

# The Measurement Interval of Cholesterol Level for the Purpose of Dyslipidemia Screening: An Open Retrospective Cohort Study

学位名	修士(公衆衛生学)
学位授与機関	聖路加国際大学
学位授与年度	2020
学位授与番号	32633公修専第063
URL	<a href="http://hdl.handle.net/10285/00016413">http://hdl.handle.net/10285/00016413</a>

## References

*Survey and statistics of dyslipidemia in Japan.* [Online]. Available from:

<http://www.seikatsusyukanbyo.com/statistics/2019/009973.php> [1]

Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., Graham, I. M., Halliday, A., Landmesser, U., Mihaylova, B., Pedersen, T. R., Riccardi, G., Richter, D. J., Sabatine, M. S., Taskinen, M. R., Tokgozoglu, L., ... ESC Scientific Document Group (2020). 2019 ESC/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. *European Heart Journal*, 41(1), 111–188. <https://doi.org/10.1093/eurheartj/ehz455> [2]

The essence of dyslipidemia treatment for the prevention of atherosclerosis. [3]

Grundy, S., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K., Blumenthal, R., Braun, L., de Ferranti, S., Faiella-Tommasino, J., Forman, D., Goldberg, R., Heidenreich, P., Hlarky, M., Jones, D. W., Lloyd-Jones, D., Lopez-Paiars, N., Ndumele, C. E., Orringer, C., Peralta, C. . . . Yeboah, J. (2019). 2018 Guideline on the management of blood cholesterol: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *American College of Cardiology*, 73 (24) e285–e350. [4]

Guidelines for prevention and treatment of dyslipidemia in adults in China (2016 Revised ed.) [5]

Ference, B. A., Ginsberg, H. N., Graham, I., Ray, K. K., Packard, C. J., Bruckert, E., Hegele, R. A., Krauss, R. M., Raal, F. J., Schunkert, H., Watts, G. F., Borén, J., Fazio, S., Horton, J. D., Masana, L., Nicholls, S. J., Nordestgaard, B. G., van de Sluis, B., Taskinen, M. R., Tokgozoglu, L., ... Catapano, A. L. (2017). Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. *European Heart Journal*, 38(32), 2459 – 2472. <https://doi.org/10.1093/eurheartj/ehx144> [6]

Glasziou, P. P., Irwig, L., Heritier, S., Simes, R., J., Tonkin, A., & LIPID study

investigators, (2008). Monitoring cholesterol levels: Measurement error or true change? *Annals Internal Medicine*, 148(9), 656 - 661. [7]

Takahashi, O., Farmer, A. J., Shimbo, T., Fukui, T., & Glasziou, P. P. (2010). A1C to detect diabetes in healthy adults: When should we recheck?. *Diabetes care*, 33(9), 2016 – 2017. <https://doi.org/10.2337/dc10-0588> [8]

Takahashi, O., Glasziou, P. P., Perera, R., Shimbo, T., Suwa, J., Hiramatsu, S., & Fukui, T. (2010). Lipid re-screening: What is the best measure and interval?. *Heart (British Cardiac Society)*, 96(6), 448 – 452. <https://doi.org/10.1136/hrt.2009.172619> [9]

Ohde, S., Deshpande, G. A., Yokomichi, H., Takahashi, O., Fukui, T., & Yamagata, Z. (2018). HbA1c monitoring interval in patients on treatment for stable type 2 diabetes. A ten-year retrospective, open cohort study. *Diabetes Research and Clinical Practice*, 135, 166 – 171. <https://doi.org/10.1016/j.diabres.2017.11.013> [10]

Perera, R., McFadden, E., McLellan, J., Lung, T., Clarke, P., Pérez, T., Fanshawe, T., Dalton, A., Farmer, A., Glasziou, P., Takahashi, O., Stevens, J., Irwig, L., Hirst, J., Stevens, S., Leslie, A., Ohde, S., Deshpande, G., Urayama, K. . . . Stevens, R. (2015). Optimal strategies for monitoring lipid levels in patients at risk or with cardiovascular disease: A systematic review with statistical and cost-effectiveness modelling. *Health Technology Assessment*, No. 19.100. <https://doi.org/10.3310/hta191000> [11]

Castañer, C., Pintó, X., Subirana, I., Amor, A. J., Ros, E., Hernáez, A. Martínez-González, M., Corella, D., Salas-Salvadó, Estruch, R., Lapetra, J., Gómez-Gracia, E., Alonso-Gomez, A. M., Fiol, M., Serra-Majem, L., Corbella, E., Benaiges, D., Sorli, J., Ruiz-Canela, M., . . . Fitó, M. (2020). Remnant cholesterol, not LDL cholesterol, is associated with incident cardiovascular disease, *Journal of the American College of Cardiology*, 76(23), 2712 - 2724. <https://www.jacc.org/doi/10.1016/j.jacc.2020.10.008> [12]